Text Size
Santen Global

2021 IR News

RSS

IR News

Santen and Aerie to accelerate global deployment of Rhopressa/Rhokiinsa and Rocklatan/Roclanda Expanding the area of exclusive licensing, including Europe and China
Corporate Governance Report
Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy
Santen to Present Latest Data on Omidenepag Isopropyl at AAO 2021
Santen Reports the 2nd Quarter Fiscal 2021 Consolidated Performance
Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution 0.02% Phase 3 Clinical Trial in Japan
Santen to Present Latest Data on STN2000100 (DE-128, MicroShunt) at 39th ESCRS
Notice of Corporate Officer Appointments
Singapore National Eye Centre and Santen Announce a Strategic Partnership to Develop and Deploy Internationally an Innovative Educational Programme for Development of the Eye Care Ecosystem in Asia
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System
Integrated Report Santen Report 2021 has been published
Santen to Present Latest Data including STN1012700 (DE-127) at APAO 2021
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System
Notice on the Selection to Apply to New Market Segment 'Prime Market' on the Tokyo Stock Exchange
Santen and Airdoc Partner to Improve Diagnostic Rate of Fundus Ocular Diseases with AI device in China
Santen Files for Manufacturing and Marketing Approval of STN1008903 (diquafosol sodium) - Improved formulation to reduce the frequency of administration to ease patients' burden -
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia
Santen Reports the 1st Quarter Fiscal 2021 Consolidated Performance
Santen to Present Latest Data including STN1012700 (DE-127) and STN1007603 (DE-076C) at 33rd APACRS 2021 meeting
Santen and IAPB taking action to implement the first ever UN General Assembly resolution recognizing the link between eye health and sustainable development
Santen to Present Latest Data on STN2000100 at 2021 ASCRS Annual Meeting
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen's CO2 emission reduction targets endorsed by the Science Based Targets (SBT) initiative
Corporate Governance Report
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen to Present Latest Data on STN2000100 at COS 2021 and 9th WGC
Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults
Santen to Present Latest Data on Omidenepag Isopropyl at APGC 2021
Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand
Santen Announces Medium-Term Plan "MTP2025"
Santen Establishes "Santen Vision for the Earth 2050" Setting Environmental Targets for 2030, Including CO2 Emissions Reduction Targets
Santen expresses a stance to strengthen its gender diversity. -Joining the "30% Club Japan," taking action to increase gender diversity at board and senior management -Becoming a signatory of the "UN Women's Empowerment Principles" promoting gender equali
Notice of Board of Director and Corporate Auditor Nominations
Santen Reports Fiscal 2020 Consolidated Performance
Notice of Postponement of Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year
Santen has commenced the construction of the new factory in Suzhou to address expanding product demand in China -Toward reinforcing global production and supply structure-
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Notice of Corporate Officer Appointments
Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year
(Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year
Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension
Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea
Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference
Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved